Skip to main content
SpringerLink
Log in

The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω 1) selective, benzodiazepine receptor ligands

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The behavioral effects of a wide range of BZ (ω) receptor ligands, including non-selective full (alprazolam, clorazepate, chlordiazepoxide and diazepam) and partial (bretazenil, imidazenil and Ro 19-8022) agonists, and selective BZ-1 (ω 1) (abecarnil, CL 218,872, CL 284,846 and zolpidem) receptor ligands, were compared in the rat elevated plus-maze test. Behaviors recorded comprised the traditional indices of anxiety as well as a number of ethologically derived measures. In addition, the specificity of drug effects was evaluated by measuring spontaneous locomotor activity in activity cages in separate groups of animals. Results showed that all compounds tested not only increased the proportion of time spent and proportion of entries into the open arms of the maze (considered as traditional indices of anxiety) but also affected headdippings and attempts at entry into open arms, which can be considered as indices of risk assessment responses. However, the magnitude of these effects was generally smaller with the BZ-1 (ω 1) selective agents. Moreover, additional differences were apparent on the total number of arm entries measure, which was significantly increased by most full and all partial agonists, but was unaffected by the selective BZ-1 (ω 1) compounds. If it is assumed that total arm entries are contaminated by anxiety, the latter finding indicates a weaker anxiety-reducing potential of selective BZ-1 (ω 1) ligands. Importantly, the increase in total arm entries induced by the non-selective agents was not associated with a similar effect on locomotion as revealed in the actimeter. Finally, anxiolysis produced by the BZ-1 (ω 1) ligands was invariably observed at doses which reduced locomotor activity, suggesting that the anxiolytic-like effects of these compounds are confounded by decreases in locomotor activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Auta J, Romeo E, Kozikowski A, Ma D, Costa E, Guidotti A (1993) Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl-3-indoleacetaminde and imidazopyridine derivatives. J Pharmacol Exp Ther 265:649–656

    PubMed  Google Scholar 

  • Belzung C, Misslin R, Vogel E (1989) Behavioural effects of the benzodiazepine receptor partial agonist RO 16-6028 in mice. Psychopharmacology 97:388–391

    Article  PubMed  Google Scholar 

  • Blanchard DC, Blanchard RJ, Tom P, Rodgers RJ (1990a) Diazepam changes risk assessment in an anxiety/defense test battery. Psychopharmacology 101:511–518

    Google Scholar 

  • Blanchard DC, Rodgers RJ, Blanchard RJ (1990b) Ethopharmacological control of fear and anxiety in the rat. In: Brain PF, Parmigiani F, Blanchard RJ, Mainardi D (eds) Fear and defence. Harwood Academic Publishers, London, pp 245–267

    Google Scholar 

  • Cole JC, Rodgers RJ (1993) An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav Pharmacol 4:573–580

    PubMed  Google Scholar 

  • Cole JC, Rodgers RJ (1994) Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology 114:288–296

    Article  PubMed  Google Scholar 

  • Cruz APM, Frei F, Graeff FG (1994) Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49:171–176

    Article  PubMed  Google Scholar 

  • Davies MF, Onaivi ES, Chen S-W, Maguire PA, Tsai NF, Loew GH (1994) Evidence for central benzodiazepine receptor heterogeneity from behavior tests. Pharmacol Biochem Behav 49:47–56

    Article  PubMed  Google Scholar 

  • Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD (1995) Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology 118:316–323

    Article  PubMed  Google Scholar 

  • Day IP, Clody DE, Monaghan MM, Abel MS, Dusza JP, Beer B (1992) Pharmacology of CL 284,846, a non-benzodiazepine sedative with reduced amnestic liability. Soc Neurosci Abstr 18:725

    Google Scholar 

  • Dazzi L, Motzo C, Imperato A, Serra M, Gessa GL, Biggio G (1995) Modulation of basal and stress-induced release of acetylcholine and dopamine in rat brain by abecarnil and imidazenil, two anxioselectiveγ-aminobutyric acidA receptor modulators. J Pharmacol Exp Ther 273:241–247

    PubMed  Google Scholar 

  • Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G (1986) Zolpidem, a novel non-benzodiazepine hypnotic: I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237:649–658

    PubMed  Google Scholar 

  • Faure-Halley C, Graham D, Arbilla S, Langer SZ (1993) Expression and properties of recombinantα 1 β 2 γ 2 andα 5 β 2 γ 2 forms of the rat GABAA receptor. Eur J Pharmacol 246:283–287

    Article  PubMed  Google Scholar 

  • File SE (1992) Behavioural detection of anxiolytic action. In: Elliott JM, Heal DJ, Marsden CA (eds) Experimental approaches to anxiety and depression. John Wiley, Chichester, pp 25–44

    Google Scholar 

  • Giusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A, Costa E (1993) Imidazenil: a new partial positive allosteric modulator ofγ-aminobutyric acid (GABA) action at GABAA receptors. J Pharmacol Exp Ther 266:1018–1028

    PubMed  Google Scholar 

  • Griebel G, Belzung C, Misslin R, Vogel E (1993) The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav Pharmacol 4:637–644

    PubMed  Google Scholar 

  • Griebel G, Moreau J-L, Jenck F, Misslin R, Martin JR (1994) Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113:463–470

    PubMed  Google Scholar 

  • Griebel G, Blanchard DC, Jung A, Blanchard RJ (1995) A model of “antipredator” defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 7:732–745

    Google Scholar 

  • Haefely W, Martin JR, Schoch P (1990) Novel anxiolytics that acts as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 11:452–456

    Article  PubMed  Google Scholar 

  • Handley SL, McBlane JW (1993) An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Methods 29:129–138

    Article  PubMed  Google Scholar 

  • Jenck F, Moreau JL, Bonetti EP, Martin JR, Haefely WE (1992) Ro 19-8022, a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potential anxiolytic. J Pharmacol Exp Ther 262:1121–1127

    PubMed  Google Scholar 

  • Jones GH, Schneider C, Schneider HH, Seidler J, Cole BJ, Stephens DN (1994) Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies. Psychopharmacology 114:191–199

    Article  PubMed  Google Scholar 

  • Knoflach F, Drechsler U, Scheurer L, Malherbe P, Mohler H (1993) Full and partial agonism displayed by benzodiazepine receptor ligands at recombinantγ-aminobutyric acidA receptor. J Pharmacol Exp Ther 266:385–391

    PubMed  Google Scholar 

  • Lader M (1994) Benzodiazepines: a risk-benefit profile. CNS Drugs 1:377–387

    Google Scholar 

  • Langer SZ, Arbilla S (1988) Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification asω receptor subtypes. Pharmacol Biochem Behav 29:763–766

    Google Scholar 

  • Lippa AS, Coupet J, Greenblatt EN, Klepner CA, Beer B (1979) A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety. Pharmacol Biochem Behav 11:99–106

    Google Scholar 

  • Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180–185

    PubMed  Google Scholar 

  • Martin JR, Pieri L, Bonetti EP, Schaffner R, Burkard WP, Cumin R, Haefely WE (1988) Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 21:360–362

    PubMed  Google Scholar 

  • Martin JR, Schoch P, Jenck F, Moreau J-L, Haefely WE (1993) Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero. Psychopharmacology 111:415–422

    PubMed  Google Scholar 

  • Ozawa M, Nakada Y, Sugimachi K, Yabuuchi F, Akai T, Mizuta E, Kuno S, Yamaguchi M (1994) Pharmacological characterization of the novel anxiolyticβ-carboline abecarnil in rodents and primates. Jpn J Pharmacol 64:179–187

    PubMed  Google Scholar 

  • Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525–529

    Article  PubMed  Google Scholar 

  • Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167

    Article  PubMed  Google Scholar 

  • Potokar J, Nutt DJ (1994) Anxiolytic potential of benzodiazepine receptor partial agonists. CNS Drugs 1:305–315

    Google Scholar 

  • Pritchett DB, Seeburg PH (1990)γ-Aminobutyric acidA receptorα 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 54:1802–1804

    PubMed  Google Scholar 

  • Pritchett DB, Lüddens H, Seeburg PH (1989) Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science 245:1389–1392

    PubMed  Google Scholar 

  • Puia G, Ducic I, Vicini S, Costa E (1992) Molecular mechanisms of the partial allosteric modulatory effects of bretazenil atγ-aminobutyric acid type A receptor. Proc Natl Acad Sci USA 89:3620–3624

    PubMed  Google Scholar 

  • Rodgers RJ, Cole JC (1993) Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors. Physiol Behav 53:383–388

    Article  PubMed  Google Scholar 

  • Rodgers RJ, Cole JC, Cobain MR, Daly P (1992a) Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav Pharmacol 3:621–634

    PubMed  Google Scholar 

  • Rodgers RJ, Lee C, Shepherd JK (1992b) Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology 106:102–110

    Google Scholar 

  • Sanger DJ (1995) The behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol 6:116–126

    PubMed  Google Scholar 

  • Sanger DJ, Perrault G, Morel E, Joly D, Zivkovic B (1991) Animal models of anxiety and the development of novel anxiolytic drugs. Prog Neuropsychopharmacol Biol Psychiatry 15:205–212

    Article  PubMed  Google Scholar 

  • Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994) Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 18:355–372

    Article  PubMed  Google Scholar 

  • Sieghart W (1995) Structure and pharmacology ofγ-aminobutyric acidA receptor subtypes. Pharmacol Rev 47:181–234

    PubMed  Google Scholar 

  • Sieghart W, Schuster A (1984) Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Biochem Pharmacol 33:4033–4038

    Article  PubMed  Google Scholar 

  • Squires RF, Benson DI, Braestrup C, Coupet J, Klepner CA, Myers V, Beer B (1979) Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol Biochem Behav 10:825–830

    Google Scholar 

  • Stephens DN, Voet B (1994) Differential effects of anxiolytic and non-anxiolytic benzodiazepine receptor ligands on performance of a differential reinforcement of low rate (DRL) schedule. Behav Pharmacol 5:4–14

    PubMed  Google Scholar 

  • Stephens DN, Schneider HH, Kehr W, Andrews JS, Rettig KJ, Turski L, Schmiechen R, Turner JD, Jensen LH, Petersen EN et al. (1990) Abecarnil, a metabolically stable, anxioselectiveβ-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 253:334–343

    PubMed  Google Scholar 

  • Treit D (1985) Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev 9:203–222

    Article  PubMed  Google Scholar 

  • Treit D, Menard J, Royan C (1993) Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44:463–469

    Google Scholar 

  • Wafford KA, Whiting PJ, Kemp JA (1993) Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinantγ-aminobutyric acid receptor subtypes. Mol Pharmacol 43:240–244

    PubMed  Google Scholar 

  • Zivkovic B, Morel E, Joly D, Perrault G, Sanger DJ, Lloyd KG (1990) Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry 23 [Suppl 3]:108–113

    PubMed  Google Scholar 

  • Zivkovic B, Perrault G, Sanger D (1992) Receptor subtype-selective drugs: a new generation of anxiolytics and hypnotics. In: Mendlewitz J, Racagni G (eds) Target receptors for anxiolytics and hypnotics: from molecular pharmacology to therapeutics. Karger, Basel, pp 55–73

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CNS Research Department, Synthélabo Recherche, 31 Avenue Paul-Vaillant Couturier, F-92220, Bagneux, France

    G. Griebel, D. J. Sanger & G. Perrault

Authors
  1. G. Griebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. J. Sanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Perrault
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Griebel, G., Sanger, D.J. & Perrault, G. The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω 1) selective, benzodiazepine receptor ligands. Psychopharmacology 124, 245–254 (1996). https://doi.org/10.1007/BF02246664

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02246664

Key words

Search

Navigation